Ex Vivo Stimulation of Tumor-Draining Lymph Node Cells from Lung Cancer Patients: A Potential Resource for Adoptive Immunotherapy

Shan, Baoen; Li, Qiliang; He, Mingwei; He, Yutong

doi:10.1038/cmi.2008.38

Cited by 4 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, tumor‐draining lymph nodes (TDLNs) are the first immune‐inducing sites receiving tumor antigens. [ 31 ] To elucidate the adaptive immune response induced by the treatment, TDLNs from tumor‐bearing mice were collected 7 days post treatment ( Figure A). The maturation of DCs in TDLNs was analyzed by flow cytometry of the expression of CD86 and MHC‐II.…”

Section: Resultsmentioning

confidence: 99%

In Situ Tumor Vaccination with Calcium‐Linked Degradable Coacervate Nanocomplex Co‐Delivering Photosensitizer and TLR7/8 Agonist to Trigger Effective Anti‐Tumor Immune Responses

Liu

Zhao

et al. 2022

Adv Healthcare Materials

View full text Add to dashboard Cite

In situ anti-tumor vaccination is an attractive type of cancer immunotherapy which relies on the effectiveness of dendritic cells (DCs) to engulf tumor antigens, become activated, and present antigens to T cells in lymphoid tissue. Here, a multifunctional nanocomplex based on calcium crosslinked polyaspartic acid conjugated to either a toll-like receptor (TLR)7/8 agonist or a photosensitizer is reported. Intratumoral administration of the nanocomplex followed by laser irradiation induces cell killing and hence generation of a pool of tumor-associated antigens, with concomitant promotion of DCs maturation and expansion of T cells in tumor-draining lymph nodes. Suppression of tumor growth is observed both at the primary site and at the distal site, thereby hinting at successful induction of an adaptive anti-tumor response. This strategy holds promise for therapeutic application in a pre-operative and post-operative setting to leverage to mutanome of the patient's own tumor to mount immunological memory to clear residual tumor cells and metastasis.

show abstract

Section: Resultsmentioning

confidence: 99%

In Situ Tumor Vaccination with Calcium‐Linked Degradable Coacervate Nanocomplex Co‐Delivering Photosensitizer and TLR7/8 Agonist to Trigger Effective Anti‐Tumor Immune Responses

Liu

Zhao

et al. 2022

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…TDLNs are a good source for ex vivo expansion of immune cells. 40 41 Tumor-reactive T-cells in non-metastatic LNs can be expanded in vitro, 1 indicating their potential for ACT. Lymphocytes in SLNs are the first LNs to receive tumor antigen stimulation and possess potent tumor recognition-specific immune memory and are considered an ideal starting source of cells for ACT.…”

Section: Contribution Of Tdlns To the Crc Response To Immunotherapymentioning

confidence: 99%

Tumor-draining lymph nodes: opportunities, challenges, and future directions in colorectal cancer immunotherapy

Wang,

Zhu,

Shi

et al. 2024

J Immunother Cancer

View full text Add to dashboard Cite

Tumor-draining lymph nodes (TDLNs) are potential immunotherapy targets that could expand the population of patients with colorectal cancer (CRC) who may benefit from immunotherapy. Currently, pathological detection of tumor cell infiltration limits the acquisition of immune information related to the resected lymph nodes. Understanding the immune function and metastatic risk of specific stages of lymph nodes can facilitate better discussions on the removal or preservation of lymph nodes, as well as the timing of immunotherapy. This review summarized the contribution of TDLNs to CRC responses to immune checkpoint blockade therapy, local immunotherapy, adoptive cell therapy, and cancer vaccines, and discussed the significance of these findings for the development of diagnostics based on TDLNs and the potential implications for guiding immunotherapy after a definitive diagnosis. Molecular pathology and immune spectrum diagnosis of TDLNs will promote significant advances in the selection of immunotherapy options and predicting treatment efficacy.

show abstract

Current World Literature

2009

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

Ex Vivo Stimulation of Tumor-Draining Lymph Node Cells from Lung Cancer Patients: A Potential Resource for Adoptive Immunotherapy

Cited by 4 publications

References 22 publications

In Situ Tumor Vaccination with Calcium‐Linked Degradable Coacervate Nanocomplex Co‐Delivering Photosensitizer and TLR7/8 Agonist to Trigger Effective Anti‐Tumor Immune Responses

In Situ Tumor Vaccination with Calcium‐Linked Degradable Coacervate Nanocomplex Co‐Delivering Photosensitizer and TLR7/8 Agonist to Trigger Effective Anti‐Tumor Immune Responses

Tumor-draining lymph nodes: opportunities, challenges, and future directions in colorectal cancer immunotherapy

Current World Literature

Contact Info

Product

Resources

About